India, Nov. 6 -- The Government of India has issued a release:
Affordable, quality cancer care for every family is a priority for the Government of India. On October 17, 2026, the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin on 137 non-scheduled anti-cancer medicines, including patented ones, at 30% of the maximum retail price (MRP). The revised prices take effect on November 9, 2026. By November 4, 2026, 70 companies had reported revised MRPs for 120 drugs, with the highest reduction at 96.45% and estimated savings of Rs. 3,357.49 crore. MRP reductions average 20% to 70%.
Cancer Medicine Prices Reduced by 20% to 70% on Average
What Is a Trade Margin?
Trade margin is the difference between the price a manufacturer charges a stockist/distributor and the highest price (MRP) a patient pays for a medicine excluding Goods and Services Tax (GST). When this trade margin is very high, large profits are added along the supply chain. This heavily inflates the final cost for patients, making already expensive cancer drugs far more costly than the price at which the manufacturer sells them.
How Medicine Prices Are Regulated
What Is the National List of Essential Medicines?
The National List of Essential Medicines (NLEM) is an official list of necessary, high-priority medicines for India. Its latest revision, NLEM 2022, was released by Union Health Minister Dr. Mansukh Mandaviya on September 13, 2022, under the Government's vision of "Sabko Dawai, Sasti Dawai" (Medicine for everyone, affordable medicine).
How the New Order Limits Trade Margins on Cancer Medicines
Sr. No.
Name of the Drug
Sr. No.
Name of the Drug
1
Abemaciclib
70
Lenvatinib
2
Abiraterone acetate
71
Lomustine
3
Acalabrutinib
72
Lorlatinib
4
Afatinib
73
Lymphoseek kit
5
Alectinib
74
Megestrol
6
Alpelisib
75
Midostrurin
7
Amivantamab
76
Mirvetuximab soravtansine
8
Anastrazole
77
Mitomycin
9
Apalutamide
78
Mitoxantrone
10
Asciminib
79
Nelarabine
11
Atezolizumab
80
Netupitant
12
Avelumab
81
Nilotinib
13
Axitinib
82
Nimotuzumab
14
Azacitidine
83
Nintedanib
15
Belantamab Mafodotin
84
Niraparib
16
Bevacizumab
85
Nivolumab
17
Bosutinib
86
Obinutuzumab
18
Brentuximab Vedotin
87
Ofatumumab
19
Brigatinib
88
Olaparib
20
Busulfan
89
Osimertinib
21
Cabazitaxel
90
Palbociclib
22
Cabozantinib (S)- Maleate
91
Panitumumab (Vectibix)
23
Capmatinib
92
Pazopanib (as Hydrochloride)
24
Carfilzomib
93
Pegasparginase
25
Carmustine
94
Pegfilgrastim
26
Ceritinib
95
Pegylated interferon Alpha 2B
27
Cetuximab
96
Pembrolizumab
28
Cladribine
97
Pemetrexed
29
Clofarabine
98
Pertuzumab
30
Crizotinib
99
Pertuzumab + Trastuzumab
31
Cytarabine
100
Plerixafor
32
Dabrafenib
101
Polatuzumab Vedotin
33
Dacomitinib
102
Pomalidomide
34
Daratumumab
103
Ramucirumab
35
Darolutamide
104
Regorafenib
36
Dasatinib
105
Relugolix
37
Datopotamab Deruxtecan
106
Ribociclib
38
Decitabine
107
Rucaparib
39
Degarelix
108
Ruxolitinib
40
Denosumab
109
Selpercatinib
41
Dostarlimab
110
Selumetinib
42
Durvalumab
111
Serplulimab
43
Elranatamab
112
Sotorasib
44
Enfortumab vedotin
113
Sunitinib
45
Entrectinib
114
Talquetamab
46
Enzalutamide
115
Teclistamab
47
Epirubicin
116
Tegafur + Uracil
48
Erdafitinib
117
Tegafur, Gimeracil and Oteracil
49
Eribulin mesylate
118
Temsirolimus
50
Erlotinib
119
Tepotinibe
51
Estramustine
120
Thiotepa
52
Everolimus
121
Tislelizumab
53
Exemestane
122
Tocilizumab
54
Fludarabine
123
Topotecan
55
Fulvestrant
124
Toripalimab
56
Gilteritinib
125
Trabectedin
57
Goserelin acetate
126
Trametinib
58
Ibritumomab
127
Tremelimumab
59
Ibrutinib
128
Treosulfan
60
Idelalisib
129
Trifluridine + Tipiracil
61
Ifosfamide & Mesna
130
Triptorelin
62
Nivolumab and Relatimab
131
Tucatinib
63
Pegylated Liposomal Irinotecan
132
Vemurafenib
64
Inotuzumab Ozogamicin
133
Venetoclax
65
Interferon Alpha 2B
134
Vinorelbine tartrate
66
Ipilimumab
135
Vorasidenib
67
Ivosidenib
136
Zanubrutinib
68
Lapatanib
137
Zolbetuximab
69
Lazertinib
Wider Government Support for Cancer Care
Making Cancer Treatments Affordable and Accessible
History: First created in 1996, then updated in 2003, 2011, 2015, and 2022.
Who Made It: An expert panel called the Standing National Committee on Medicines (SNCM), after talking with doctors, scientists, industry experts, and checking WHO standards.
Why the List Matters
The Legal Power Behind the Order: Paragraph 19 of the DPCO, 2013
The Government has capped excessive markups along the pharmaceutical supply chain, in retail and hospital pharmacies across the country, to make cancer treatment in India more affordable.
The Order sets the new maximum retail price of each medicine from its average distributor price of March 2026. The trade margin within that price can be no more than 30%, and GST is added on top.
How the New Maximum Retail Price (MRP) Is Calculated
The Order sets the formula for the maximum retail price a patient can be charged:
Anti-Cancer Medicines Covered by the Order
Source: Ministry of Chemicals and Fertilizers, NPPA Order S.O. 5690(E) of October 17, 2026
What Changes for Patients and Companies
The Government runs various health programmes to provide affordable cancer care treatment, screenings and medicines for the public.
AB-PMJAY: Cashless Hospital Care, Including Cancer Treatment
NP-NCD: Cancer Care from Screening to Treatment
Screening for Common Cancers at Primary Healthcare Centres
Free HPV Vaccination to Prevent Cervical Cancer
Low-Cost Medicine Outlets: Jan Aushadhi and AMRIT
Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)
Affordable Medicines and Reliable Implants for Treatment Pharmacies
Teleconsultations for Cancer Care
Teleconsultation services are provided through the eSanjeevani platform to improve access to specialist care, particularly in remote and underserved areas. This includes oncology care.
The trade margin cap adds to the support the Government already gives at every stage of cancer care: screening at Ayushman Arogya Mandirs, free HPV vaccination for girls, cashless hospital treatment under AB-PMJAY, and lower-cost medicines at Jan Aushadhi Kendras and AMRIT pharmacies. Together, these measures bring quality cancer care within reach of more families, closer to where they live.
References
Ministry of Chemicals and Fertilizers
https://www.pib.gov.in/PressReleasePage.aspx?PRID2321092®48&lang2
https://www.pib.gov.in/PressReleasePage.aspx?PRID2324743
https://nppa.gov.in/storage/uploads/tender/277271-17-10-2026.pdf
https://www.pib.gov.in/PressReleasePage.aspx?PRID2297568®3&lang1
https://nppa.gov.in/storage/uploads/pdf/DPCO-inclusive-of-all-ammendmentscompressedpdf-6f9edc1bf7c000eb02b7eee6c180b527.pdf
https://nppa.gov.in/en/search_medicine_price
https://www.pib.gov.in/PressReleasePage.aspx?PRID2329698
https://nppa.gov.in/storage/uploads/tender/revised-mrp-report-04112026-04-11-2026.pdf
https://x.com/nppa_india/status/2117986916121628974
https://x.com/Pharmadept/status/2117305360692466164
Ministry of Health and Family Welfare
https://www.pib.gov.in/PressReleasePage.aspx?PRID1858931®48&lang2
https://www.pib.gov.in/PressReleasePage.aspx?PRID2286948®48&lang2
https://www.pib.gov.in/PressReleasePage.aspx?PRID2294278
https://dashboard.nha.gov.in/public/
https://sansad.in/getFile/lsapps/loksabhaquestions/annex/188/AU931_DhFQWt.pdf
https://elibrary.sansad.in/server/api/core/bitstreams/b3b40e24-2357-43ce-b2ec-89a9d548f521/view
https://www.pib.gov.in/PressReleaseDetail.aspx?PRID2309109®3&lang1
https://esanjeevani.mohfw.gov.in/
https://www.pib.gov.in/PressReleasePage.aspx?PRID2314433®48&lang2
PIB Backgrounders
https://www.pib.gov.in/FactsheetDetails.aspx?Id150834®5&lang1
Click to see pdf
Disclaimer: Curated by HT Syndication.